One of the major problems after allogeneic bone marrow transplantation (BMT) is a high frequency of leukemia relapse. We have prospectively studied the presence of donor-and recipient-derived chimeric cells in bone marrow recipients with pre-B cell acute lymphoblastic leukemia (pre-B-ALL). The chimeric status of BMT recipients was compared to minimal residual disease 
chromosomal abnormalities (t [4:11] , t [8:14] and t [9:22] ), B cell phenotype, Ͼ100 × 10 9 /l WBC at diagnosis, CNS involvement and failure to obtain remission within 6 weeks of chemotherapy. 4 The relationship between submicroscopic residual leukemic hematopoietic cell numbers and leukemia-free survival (LFS) after treatment of patients with ALL has been debated. 5, 6 Although no threshold value is uniformly associated with relapse, the presence of minimal residual disease (MRD) above a 10 −3 -10 −5 level after BMT is believed to predict disease relapse for ALL and chronic myeloid leukemia (CML). [7] [8] [9] [10] [11] The use of PCR to amplify clonal IgH and TcR gene rearrangements has so far provided the most sensitive means for the analyses of MRD levels in patients with B-ALL, 12, 13 whereas PCR amplification of variable number repeat regions (VNTRs or STRs) is regarded as a more universal marker for the identification of alleles from different patients. 14 In BMT, these VNTRs or STRs can thus be used to evaluate various degrees of donor/recipient MC. 15, 16 There is still no agreement about PCR of VNTRs or STRs for relapse prediction post BMT because of their low specificity. The use of clonally rearranged VDJ genes is accepted as a reliable disease relapse predictor in ALL. 9 This is probably due to greater sensitivity (10 −5 level), and to the fact that the DNA sequence achieved is a more specific leukemia marker. A disadvantage of VDJ analysis is a high frequency of changes in rearrangement patterns. 13, 17 Furthermore, it is a cumbersome and often a time-consuming technique.
The aim of the present study was to investigate whether analysis of MC within the affected cell lineage correlated temporally to the presence of residual leukemia and relapse after BMT.
Materials and methods

Patients and donors
Twelve patients with ALL were studied. Eleven of them had pre-B-ALL and one had biphenotypic ALL. BMT was performed between September 1996 and December 1997 at the BMT Unit, Huddinge Hospital. Median follow-up time was 12.5 months (3-24 months). Three patients received marrow from HLA-identical siblings, seven from HLA-A, -B and -DR compatible unrelated donors and two from 1 Ag mismatched unrelated donors (Table 1) . HLA class I typing was performed serologically and class I subtyping, as well as class II typing, were performed genomically. 18 All patients were treated with cyclophosphamide 60 mg/kg for 2 days and were given two 12 mg doses of intrathecal methotrexate (MTX). In addition, patients with HLA-compatible donors received 10 Gy of total body irradiation (TBI), as previously described. 19 The recipients of mismatched unrelated marrow received fractionated TBI 1.8 Gy twice daily for 4 consecutive days (total 14.4 Gy), according to the Bristol protocol. 20 Prior to BMT, all patients receiving marrow from unrelated donors were given 5 days of anti-T cell globulin (ATG) or OKT-3. 19 Mismatched unrelated marrow was depleted of T cells by adding magnetic beads (Dynal, Oslo, Norway) coupled with monoclonal antibodies directed against CD2, CD3 and CD8. As prophylaxis against GVHD, cyclosporin A was combined with a short course of MTX. 21 Details regarding the transplantation procedure and supportive care have been published elsewhere. 19, 22 A patient with regenerating peripheral blood values was considered in clinical remission when fewer than 5% blast cells among at least 200 nucleated cells were found in a BM sample, as defined by morphology. Clinical leukemic relapse was defined as when at least 30% blast cells were found in BM, or when leukemic cells were detected in peripheral blood.
PCR amplification template preparations
DNA from donor and recipient pre-transplantation samples was extracted using standard protocols (Qiagen, Hilden, Germany). Separation of CD3, CD19 and CD45-positive cells from 4 ml of EDTA blood was performed with immunomagnetic beads, according to the manufacturer (Dynal). To each cell pellet, 30 l 10 mm Tris buffer was added before freezing. After thawing, 60 l lysis-buffer (18 l 5x red cell lysis buffer (1.6 m sucrose, 0.05 m Tris-HCl, 25 mm MgCl 2 6H 2 O, 5% Triton-X-100, 0.01 m Tris-Base), 8 l proteinase K (10 mg/ml), 34 l distilled H 2 O) was added to each bead-selected sample. Samples were then digested at 37°C overnight on a shaker. CD19-positive samples were diluted in 100-300 l 10 mm Tris buffer, pH 6.6. CD3-positive and CD45-positive samples were diluted in 1000 l 10 mm Tris buffer, pH 6.6. Prior to PCR, diluted cell lysate samples were heated to 70°C for 10 min and then spun for 1 min, 10 000 r.p.m. in a microcentrifuge, and cooled on ice. For chimerism analysis, PCR amplification was performed using 10 ng of genomic DNA or 2 l (10-20 ng) of cell lysate DNA. Genomic DNA concentrations were measured in a Gene Quant II spectrophotometer (Pharmacia, Uppsala, Sweden), but cell lysate DNA was estimated by a semiquantitative dotMETRIC assay (NMI, San Diego, CA, USA).
Flow cytometry
To verify the purity of the bead-selected samples and to be able to run cells through the flow cytometer, we used DETACHaBEAD (Dynal), according to the manufacturer ' 
VNTR analysis
PCR amplifications of six different minisatellite loci were used for analysis of MC. [23] [24] [25] [26] [27] [28] All oligonucleotide primers were synthesized commercially (Cybergene, Huddinge, Sweden). Each final PCR reaction (10 l) contained 0.5 m of each primer, 200 m of each dNTP (Perkin Elmer, Branchburg, CA, USA), 1x PCR-buffer (50 mm Mg, 10 mm KCl, 0.001% gelatine), 5% glycerol, 1 ng cresol red, 10-20 ng genomic DNA, 0.3 U AmpliTaq polymerase (Perkin Elmer). After an initial 3 min hot-start/denaturation step at 94°C, 32 PCR amplification cycles were carried out in a PTC-200 thermal cycler (MJ Research, Watertown, CA, USA). The first 10 amplification cycles in a two-segment step at 94°C for 15 s and at 65°C for 1 min. The following 22 cycles in a three-segment step at 94°C for 15 s, 61°C for 50 s and 72°C for 30 s. PCR amplified products were run on a ready-to-use PAGE system (Pharmacia Biotech, Uppsala, Sweden). 12.5% non-denaturing polyacrylamide gels were run for 1.5 hours under standard buffer conditions at 10°C in a Genephor peltier-cooled gel apparatus (Pharmacia Biotech). PCR amplified band patterns were analyzed in visible light after a 90 min fully automated silver staining procedure (Pharmacia Biotech). We used a semiquantitative estimation of MC, where recipient band intensity was compared to donor band intensity on a fourdegree scale. MC +3 indicated equal recipient − donor band intensity. After digital photo-documentation, PAGE gels were sealed in hybridization bags and stored at +4°C, for future reference.
Analysis of IgH-and TcRѨ genes
PCR amplification of IgH genes used a degenerate primer complementary to framework three (FR3) of the IgH variable (V H ) gene-segments, together with a consensus joining (J H ) [1] [2] [3] [4] [5] [6] gene-segment primer 29, 30 (Table 2) . PCR amplifications of TcRѨ genes used a specific VѨ2 gene-segment primer together with a specific DѨ3 gene-segment primer 12, 31 (Table 2) . PCR amplification conditions were identical with VNTR amplification conditions, except that 100 ng genomic DNA was used in each PCR amplification reaction and that 35 amplification cycles were carried out, thus adding three cycles of the three-segment step to the PCR program used for VNTR analysis. DNA was extracted from leukemic cells obtained at diagnosis or from pre-BMT relapse samples. PCR products were electrophoresed, and single bands were excised from preparative 2% GTG agarose gels. Excised bands were purified using the QIAquick Gel Extraction Kit (Qiagen), according to the guidelines of : 5Ј-acacggc(c/t)(g/c)tgtattactgt-3Ј and Jpst: 5Ј-aactgcagaggagacggtgacc-3Ј. Primers used for PCR amplification of the TcR gene segments were V 2: 5Ј-cttgcaccatcagagagaga-3Ј and D 3: 5Ј-agggaaatggcacttttgcc-3Ј. One of the two N regions, the N1 region, was used to accommodate the 3Ј-ends of the 5Ј-patient-specific primers used for MRD detection in post-BMT samples. The Jpst primer and the D 2 primer were thus used as 3Ј-primers in the semi-nested patient-specific or 'serial', PCR. The sequence of the N2 region of IgH genes was used for specificity control of patientspecific primers. For specificity control of patient-specific TcR primers, sequences of N1 regions were only partly used as patient specific-primer sequence.
The correct remaining part of N1 sequence could thus be used as specificity control.
the manufacturer. Purified PCR products were ligated into TA vectors and subsequently transformed into competent cells, as described in the pGEM-T Easy Vector System 1 protocol (Promega, Madison, WI, USA). Plasmids from 10 independent clones were purified, using the Plasmid Mini Kit (Qiagen), and unidirectionally sequenced with a T7 vector-specific primer, using the ABI prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer). Sequences were analyzed on a 373A DNA sequencer (Applied Biosystems, Foster City, CA, USA). The predominant nucleotide sequence derived from the various plasmid clones of each patient was studied. The sequence from the N1 regions (Table 2 ) of rearranged VDJ genes was used to accommodate the 3Ј-end of the 5Ј-patient-specific primer used for each patient. Jpst and Dd3 were used as 3Ј-primers for serial analysis of IgH genes and for TcRѨ genes, respectively (Table 2) . After an initial 3-min hotstart/denaturation step, 35 PCR amplification cycles were carried out in a PTC-200 (MJ Research). The first 10 amplification cycles in a two-segment step were at 94°C for 20 s and at 65°C for 1 min. The following 25 cycles in a threesegment step were at 94°C for 20 s, 61°C for 50 s and 72°C for 20 seconds. PCR amplified specific products of 70-100 bp size were analyzed on the same PAGE system as described for VNTR analysis. To prove that a PCR product from a post-BMT sample originated from the same leukemic clone as the clone found at diagnosis or relapse pre-BMT, sequencing (as described above) was performed on most positive post-BMT samples. The retrieval of a correct N2 sequence (IgH-derived sequences) or a correct part of the N1 sequence (TcRѨ-derived sequences) was considered evidence of clonal identity.
Statistical analysis
Leukemia-free survival (LFS) in the two groups was calculated using the Kaplan-Meier product-limit method. 32 The differences between the DC and the MC groups were compared with the log-rank test.
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Results
DNA samples
Freeze-stored genomic DNA could be reanalyzed indefinitely. Cell lysate DNA could be safely reanalyzed four to five times, including freezing-thawing between subsequent analyses. After 10-12 repeated freeze-thawings of the same lysate sample, fragmentation of template DNA was observed. As a result of this DNA deterioration, the smaller chimeric DNA fraction was sometimes lost after five to 10 repetitive freeze-thawings. When a MC sample was split into 20 sample fractions, the smaller fraction band was seen in 20/20 MC samples, indicating a low intra sample variability (data not shown).
Purity of immunomagnetic selection
Purity of the CD19 beaded cell fraction was assayed by flow cytometry (Figure 1 ). The CD19-positive cell fraction (Figure 1, R4) was 95% pure. The cell debris fraction (Figure 1, R6 ) contained 4% CD19-positive cells. Therefore, after subtraction of the cell debris fraction, the purity of B cells could be estimated to be 98%.
Dilution series
When tested on a DNA dilution series, all six VNTRs had a sensitivity down to the 2% level. In a whole EDTA blood dilution series, a sensitivity down to 0.5% was achieved, but only in three of 13 aliquots of the same diluted blood sample (data not shown). In a cellular dilution series, B cells of an individual 'A' were diluted in whole EDTA blood with a known total WBC of individual 'B'. CD19-positive cells were then immunomagnetically collected in an 'affected cell-lineage'-specific manner, and a sensitivity down to 2 × 10 −4 was achieved, most likely due to reduction of irrelevant background (Figure 2 ). Using IgH patient-specific primers and an excess DNA template concentration of 200 ng in each PCR reaction, a sensitivity of 1 × 10 −4 was routinely achieved.
Patients
In this study, 5/12 patients showed MC in the B cell lineage in peripheral blood and/or bone marrow. Four of the patients with MC have relapsed to date. In the remaining seven patients without MC, no one has relapsed to date, Bone Marrow Transplantation with a median follow-up time of 17 (9-24) months (P = 0.01). In three patients who subsequently relapsed, MC in the B cell lineage was detected 2.5-4 months prior to morphologically verified relapse (Figure 3 ). Patient UPN586, who was not in CR at the time of BMT, was MRD-positive in all analyzed samples (Figures 3, and 4b) . MC in the B cell lineage was detected on day 73 post BMT, still more than 100 days before morphological relapse (Figure 4a ). In the remaining relapsed patient, UPN576, no sample could be obtained at 2 months, and MC and early morphological relapse were detected simultaneously at 3 months post BMT. In UPN 616, MC and MRD were detected in BM, but not in peripheral blood. On two separate occasions at 1 and 3 months post BMT she was morphologically in remission. UPN 597 showed MC in the B cell lineage in six samples between 2 and 9 months post BMT. At 3 months post BMT, the immunosuppression was tapered as a result of the MC detected in the B cell lineage. On three separate occasions at 3, 4 and 6 months post BMT he was morphologically in remission.
A monoclonal IgH-and/or a TcRѨ-sequence was present in pre-BMT relapse samples from 9/12 patients, and patient-specific primers could be readily designed (Table 2) . Oligoclonal sequences were detected in the remaining three patients, and no patient-specific primers were therefore obtained in these three patients. In all five patients with MC in the B cell lineage, the leukemia-specific clone pre-BMT was also recovered in post-BMT samples. In five of seven patients with donor chimerism, no leukemia-specific clone could be detected post BMT (Figure 3) . In UPN 597, the patient-specific TcR␦ clone of the relapse sample pre-BMT was recovered in all CD19 samples between 2 and 9 months (Figure 5b ). This correlated to the MC status (Figure 5a Don  CD3  CD45  CD3  CD45  CD3  CD45  CD19  CD3  CD45  CD19  CD3  CD45  CD19  CD3  CD45  CD19  CD3  CD45  CD19   100 bp  dH20  Don  Pat  +31  +73  +104 In UPN 571, a leukemia-specific clone was detected at the time of BMT as well as 1-3 months post BMT, although she was donor-chimeric in all samples post BMT and in morphological remission.
Discussion
In this study, we aimed to investigate whether MC analysis was rapid, simple and sensitive enough to predict leukemic relapse, as was recently proposed by others. 34, 35 To be certain of a relevant level of detection, we compared our MC results with current protocols for MRD detection, using PCR amplification of rearranged IgH and TcRѨ genes. 31, 36 We studied patients with pre-B-ALL, since the affected cell lineage (B cells) could be readily separated from a hypothetically 'irrelevant' hematopoietic background. We found that chimerism analysis in a separated smaller and potentially leukemic cell fraction can reach a higher sensitivity level than previously described (Figure 2) . Consequently, MC as detected by PCR amplification of VNTRs in the affected cell lineage was per se an early sign of MRD, which was clinically manifested as a leukemia relapse post BMT. MRD could also be molecularly confirmed by amplification and sequencing of clonally rearranged IgH and TcR genes.
The use of cell sorting before PCR analysis of repetitive genomic individual markers has been done to investigate Pat  Don  CD3  CD45  CD19  CD3  CD45  CD19  CD3  Cd45  CD19  CD3  CD45 the nature of MC in various cell lineages post BMT and under the influence of various conditioning treatments. 16, [37] [38] [39] Lately, MC detection of Ficoll-Hypaque density gradientseparated cell lineages has been shown to permit detailed monitoring of changes in donor/recipient cell dynamics in specific lineages following donor lymphocyte infusion (DLI) in a small number of CML patients. 40 Ramirez and co-workers 34 used Ficoll-gradient separated mononuclear vs granulocytic cell populations in patients with ALL, in an attempt to detect MC in the cell population specifically containing the leukemic clone. Even though they could detect increasing amounts of recipient cells in samples from all patients who subsequently relapsed (6/15), only two showed MC in the mononuclear cell fraction exclusively, presumably due to incomplete cell separation. Immunomagnetic bead separation prior to MC detection has also been reported. 37, 40 Unfortunately, DNA in these cases was purified from the selected cell suspensions, probably with a significant loss of DNA yield as a consequence. Detection of residual leukemic cells at the detection limit of current PCR-based strategies are often analyzed at the level of single cell(s) per sample. Therefore, to avoid any loss of DNA, we have abandoned any unnecessary physical manipulation with the target, before PCR analysis. This was done by application of modified cell lysis protocols, originally used for single cell detection. 16, 41 We believe that this singletube target handling, in combination with an efficient PCR compatible cell lysis buffer and stringent cell separation of a potentially leukemic cellular subgroup, explains why a detection limit of 2 × 10 −4 could be reached in this study. Flow cytometric assessment of the purity of selected cell Bone Marrow Transplantation fractions indicated a purity of 98% in the positively selected CD19 cell fraction from peripheral blood (Figure 1 ). Simmons and co-workers 42 have shown that levels of potentially contaminating cells in bone marrow were often of recipient origin, but macrophages were exclusively of donor origin. Therefore, a potential risk of false positive results may derive from MC analysis of contaminating stromal cells. In our experience, MC in immunomagnetically selected hematopoietic cell lineages from bone marrow, often indicates the true MC situation.
While it was initially believed that complete donor hematopoiesis was essential for sustained engraftment following allogeneic BMT, it is now clear that persistence of recipient cells can be compatible with prolonged disease-free survival. 38, 43 In particular, MC in the T cell lineage has been shown not to correlate with a subsequent relapse, but instead is thought to reflect a state of peripheral expansion of mature T cells from the grafted bone marrow during immune reconstitution. 44 In our experience, with a larger cohort of 65 patients with hematological malignancies, MC in the B cell lineage remains a rare event. MC in the B cell lineage was seen in only 9/65 patients, all of whom had disease of the B cell lineage (five B-ALL, three B-CLL and one biphenotypic AML).
In a small number of patients who subsequently relapsed with B-ALL after chemotherapy, Roberts and co-workers 6 recently showed that the fraction of residual leukemia prior to relapse was around one leukemic cell in 10 000 normal cells. Furthermore, evidence of persistent residual leukemia of the same (or slightly lower) magnitude was detected in 15 of 17 patients with B-ALL who remained in long-term remission. No threshold value could be identified as uniformly associated with leukemia relapse, whereas a trend towards increasing levels of residual leukemia in subsequent samples was significantly associated with relapse. In two recent publications 34, 35 concerning patients treated with BMT for B-ALL, increasing MC has been correlated to relapse. Although this concept seems seductive, one should be aware that other studies have failed to show this correlation. 45, 46 The reasons for the contrary results may be variant penetration of clinical outcome depending on the underlying disease and on the influence of graft-versus-leukemia. Another explanation may be patient selection. For example, in this study three of four patients who relapsed were not in clinical remission (CR) at the time of BMT, as compared to one relapse in eight patients, who were in remission at BMT. Furthermore, analysis of clonal diversity at leukemia presentation has recently been shown to affect the prognosis of patients with pre-B ALL. 47 Although MC in the B cell lineage in this study seems to reflect residual leukemia, it may simply reflect the presence of significantly higher levels of MRD prior to BMT. Thus, to highlight the risk of relapse for the high-risk group of patients, it may be rewarding not only to focus on frequent post-BMT monitoring for MC analysis, but also to study the kinetics of tumor burden reduction during pre-BMT conditioning treatment using quantitative assessment of MRD. 48 We believe that quantitative assessments of MRD before BMT could act in concert with MC analysis to identify the proper timing for early intervention. Furthermore, chimerism analysis in an affected cell lineage may both reduce the risk of false positive results due to a low detection level as well as reduce the risk of false negative results based on clonal rearrangements, due to clonal change and oligoclonality. 49, 50 In conclusion, MC in the affected cell lineage, as detected by PCR amplification of hypervariable regions (VNTRs), is almost as sensitive (10 −4 level) as an optional further analysis of specificity by PCR amplification and sequencing of VDJ gene junctional regions (10 −5 level). Clearly, these two variant strategies represent a valuable complement on the same theme -sensitive detection of leukemia recurrence. Although the findings of this study need confirmation in larger studies, we believe that analysis of MRD during conditioning treatment pre-BMT, followed by a more rapid monitoring of MC post BMT provide the necessary tools for early intervention with dose reduction of immunosuppression and/or treatment with DLI in highrisk patients with pre-B-ALL. [51] [52] [53] 
